메뉴 건너뛰기




Volumn 43, Issue 12, 2015, Pages 1663-1686

Efficacy and safety of anagliptin add to insulin therapy in Japanese Patients with type 2 diabetes-a multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an open-label, long-term extension-

Author keywords

Anagliptin; Dipeptidyl peptidase 4 inhibitor; Glucagon like peptide 1; HbA1c; Incretin; Insulin; Type 2 diabetes

Indexed keywords

ANAGLIPTIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO;

EID: 84956646510     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (1)

References (7)
  • 1
    • 44949134945 scopus 로고    scopus 로고
    • Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemie control?
    • Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemie control? Eur J Endocrinol 2008; 158 (6): 773-84.
    • (2008) Eur J Endocrinol , vol.158 , Issue.6 , pp. 773-784
    • Van Gaal, L.F.1    Gutkin, S.W.2    Nauck, M.A.3
  • 2
    • 0037241085 scopus 로고    scopus 로고
    • Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
    • Vilsbøll T, Agersø H, Kramp T, Hoist JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88 (1): 220-4.
    • (2003) J Clin Endocrinol Metab , vol.88 , Issue.1 , pp. 220-224
    • Vilsbøll, T.1    Agersø, H.2    Kramp, T.3    Hoist, J.J.4
  • 3
    • 77950880269 scopus 로고    scopus 로고
    • Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
    • Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20 (4): 224-35.
    • (2010) Nutr Metab Cardiovasc Dis , vol.20 , Issue.4 , pp. 224-235
    • Monami, M.1    Iacomelli, I.2    Marchionni, N.3    Mannucci, E.4
  • 4
    • 44949134945 scopus 로고    scopus 로고
    • Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemie control?
    • Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemie control? Eur J Endocrinol 2008; 158: 773-84.
    • (2008) Eur J Endocrinol , vol.158 , pp. 773-784
    • Van Gaal, L.F.1    Gutkin, S.W.2    Nauck, M.A.3
  • 5
    • 0025066579 scopus 로고
    • Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM
    • Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39 (11): 1381-90.
    • (1990) Diabetes , vol.39 , Issue.11 , pp. 1381-1390
    • Mitrakou, A.1    Kelley, D.2    Veneman, T.3    Jenssen, T.4    Pangburn, T.5
  • 6
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS)Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53.
    • (1998) Lancet , vol.352 , Issue.9131 , pp. 837-853
    • UK Prospective Diabetes Study (UKPDS) Group1
  • 7
    • 0035847591 scopus 로고    scopus 로고
    • Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria
    • DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
    • (2001) Arch Intern Med , vol.161 , pp. 397-405


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.